Company Overview and News

3
BlackBerry's stock jumps after profit and revenue beat expectations

2018-09-28 marketwatch
Shares of BlackBerry Ltd. BB, +14.43% rallied 3% in premarket trade Friday, after the business software company reported fiscal second-quarter earnings and revenue that beat expectations. For the quarter to Aug. 31, the company reported net income was $43 million, but a loss per diluted share of 4 cents, compared with net income of $19 million, but a loss per diluted share of 8 cents, in the same period a year ago.
BBRY

4
BlackBerry profit tops estimates on lower costs

2018-09-28 channelnewsasia
Canadian software maker BlackBerry Ltd's second-quarter profit more than doubled, helped by higher billings at its software and services business and lower costs.
AAPL BBRY

5
BBRY / BlackBerry Ltd. 6-K (Current Report of Foreign Issuer)

2018-09-28 sec.gov - 2
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BBRY

136
10 Tech Stocks That Will Disappear by 2027 – And Tesla Is One of Them

2018-09-27 investorplace - 5
A decade is a long time. But it’s even longer when it comes to tech stocks, where developments come fast and furious. Think back 10 years ago and some of the biggest technology companies of today weren’t trading publicly or in some cases didn’t even exist.
IBM FB FIT P STX GOOG BBRY GPRO AMZN GOOGL TWTR ROKU AAPL TSLA SNAP

7
BlackBerry (BB) to Report Q2 Earnings: What's in the Offing?

2018-09-26 zacks
BlackBerry Limited (BB - Free Report) is scheduled to report second-quarter fiscal 2019 financial results before the opening bell on Sep 28. The company is likely to report higher consolidated revenues on the back of healthy growth dynamics. Whether this could result into an earnings beat for the quarter remains to be seen. Key Factors to Consider After withdrawing from direct smartphone manufacturing, Blackberry has gradually transitioned into a reliable software and services firm.
CATR CAT BC94 SMSN BB BBRY AAI AA BB FLS SMSD

164
Titan Machinery, Pilgrim's Pride, Nike, Rite Aid and BlackBerry highlighted as Zacks Bull and Bear of the Day

2018-09-24 zacks - 3
Chicago, IL – September 24, 2018 – Zacks Equity Research Titan Machinery (TITN - Free Report) as the Bull of the Day, Pilgrim's Pride Corporation (PPC - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis Nike, Inc. (NKE - Free Report) , Rite Aid Corporation (RAD - Free Report) and BlackBerry Limited (BB - Free Report) .
RAD MCFT BB BBRY NKE URI LULU DXC.WI MBUU BB PPC DXC TITN TLRD

11
Did Facebook Flip The Script On BlackBerry?

2018-09-21 seekingalpha - 1
The company may have flipped the script after BlackBerry sued Facebook for patent infringement in Q1 of this year.
FB SSNLF AAPL QCOM BB BB BBRY

5
Is This The Next Big Thing In Retail?

2018-09-18 oilprice - 1
Your license and viewing of our content is subject to the disclosures contained after this article.
SHOP PSTG AWSM VEEV AAPL CLS BB BBRY

12
Citigroup hires three software investment bankers

2018-09-17 channelnewsasia
Citigroup Inc has hired three investment bankers for its technology investment banking group focused on software in the United States and in Europe, according to a memo published internally at the bank and confirmed by a spokeswoman on Monday.
DB DGLD SAPGF SFTBF CS UGLD SFTBY DSLV C VIIX CSSLF VIIZ OTEX BBRY CSGKF SAP OTC CGBBW ZIV USLV 9984 TVIX XIV

12
Citigroup hires three software investment bankers

2018-09-17 reuters
(Reuters) - Citigroup Inc (C.N) has hired three investment bankers for its technology investment banking group focused on software in the United States and in Europe, according to a memo published internally at the bank and confirmed by a spokeswoman on Monday.
DB DGLD SAPGF SFTBF CS UGLD SFTBY DSLV C VIIX CSSLF VIIZ OTEX BBRY CSGKF SAP OTC CGBBW ZIV USLV 9984 TVIX XIV

9
Why Is Apple Giving This Tiny Stock A $900 Million Opportunity?

2018-09-16 oilprice - 6
Your license and viewing of our content is subject to the disclosures contained after this article.
SHOP AWSM DSGX DALR BBRY DRLDF DNA.WT.A APH DRRLF CLS APHQF BB DNA

5
Facebook files patent infringement complaint against Blackberry in U.S. court

2018-09-05 cbc.ca
Facebook Inc. has filed a patent infringement complaint against Blackberry Ltd. in a San Francisco court.
FB BBRY

5
Facebook accuses BlackBerry of stealing voice-messaging tech

2018-09-05 livemint
Facebook Inc. is suing BlackBerry Ltd for patent infringement, escalating the legal battle between the two companies over protected technology.
FB BBRY

5
Facebook Accuses BlackBerry of Stealing Voice-Messaging Tech

2018-09-05 theedgemarkets
(Sept 5): Facebook Inc. is suing BlackBerry Ltd. for patent infringement, escalating the legal battle between the two companies over protected technology.
FB BBRY

114
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2018 Update

2018-08-16 seekingalpha - 14
Fairfax Financial’s largest three stakes are BlackBerry, Resolute Forest Products, and Kennedy Wilson. They together account for ~57% of the 13F assets.
SSYS AP FRFHF CRAY PKX MLUSG RAIL SBNY GE KWN.CL USGPF RFP MDR SSWN BBRY IPI JNJ NTES BB SSWA MCDFF AGX SSW CTL KW RFP KWN ICD GM USG IBM GEC BB CRR ARG HP FLR GNE CBI

BBRY : BlackBerry Ltd Stock Analysis and Research Report

2017-10-26 - Asif

BlackBerry is securing a connected world, delivering innovative solutions across the entire mobile ecosystem and beyond. The Company secures the world’s most sensitive data across all endpoints – from cars to smartphones – making the mobile-first enterprise vision a reality. Founded in 1984 and based in Waterloo, Ontario, the Company operates offices in North America, Europe, Middle East and Africa, Asia Pacific and Latin America. The Company’s common shares are listed on the NASDAQ Global Select Market (“NASDAQ”) (NASDAQ: BBRY) and the Toronto Stock Exchange (“TSX”) (TSX: BB), and its Debentures are listed on the TSX (TSX: BB.DB.U). The Mobile Communications Industry Improvements in wireless network infrastructure and the rapid proliferation of mobile devices and applications in recent years are transforming the way that enterprises and individuals communicate and collaborate. In the enterprise, the mobile platform is becoming the primary computing platform and users now ex...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 09228F903